查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566980

長春花生物鹼化合物市場：依產品類型、最終用戶分類：2024-2033 年全球機會分析與產業預測

Vinca Alkaloid Compounds Market By Product Type (Vinblastine, Vincristine, Vindesine) , By End User (Hospitals, Clinics, Academic & Research Institutes) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

長春花生物鹼化合物市場

2023年長春花生物鹼化合物市值為8,100萬美元，預計2024年至2033年複合年成長率為7.2%，到2033年將達到1.615億美元。

長春花生物鹼是天然存在的次級代謝物，主要從唇形科植物長春花中提取。該化合物因其抗有絲分裂和抗微管特性而被利用。在細胞分裂過程中，長春花生物鹼化合物抑制BETA-微管蛋白的聚合，BETA-微管蛋白是為細胞分裂提供結構支持所需的蛋白質。這種抑制導致細胞毒性和細胞死亡。這種化合物的特性已被用作多種癌症的治療方法，包括淋巴瘤、白血病、乳腺癌和肺癌。

各種癌症盛行率的增加和新興治療市場的開拓是長春花生物鹼化合物市場的關鍵促進因素。此外，為了開發減輕癌症的治療方法和治療解決方案而不斷進行的研究和開發工作正在推動對長春花生物鹼化合物的需求。預計利用內生菌合成這種次級代謝物將成為未來的重要趨勢。直接從植物中提取長春花生物鹼化合物效率極低且複雜。相較之下，內生菌的微生物發酵過程是一個非常可行且有效的過程，預計在未來幾年促進和促進抗癌藥物的生產。

然而，長春花生物鹼化合物的潛在副作用（例如神經毒性和骨髓抑制）很嚴重。這在一定程度上限制了該化合物的使用，並抑制了市場的開拓。此外，長春花生物鹼化合物衍生的藥物長期使用後會對癌細胞產生抗藥性，降低長期療效並阻礙市場開拓。相反，市場開拓創新正在利用長春花生物鹼化合物的抗癌作用並消除其局限性，為市場擴張提供了有利的機會。例如，根據美國國家醫學圖書館發表的一篇研究論文，透過與其他化療藥物聯合治療，長春花生物鹼化合物的副作用得到緩解，增加了雞尾酒藥物的抗腫瘤功效。

按部門審查

長春花生物鹼化合物市場按產品類型、最終用戶和地區細分。依產品類型分類，市場分為長春花鹼、長春新鹼和Vindesine。依最終使用者分為醫院、診所和學術/研究機構。從區域來看，分析包括北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按產品類型分類，長春新鹼細分市場將在 2023 年佔據主導地位。

按最終用戶分類，醫院細分市場在 2023 年佔據最高市場佔有率。

按地區分類，北美地區 2023 年收益最高。

可以自訂此報告（需要額外的費用和時間表）

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章長春花生物鹼化合物市場：依產品類型

  • 市場概況
  • 長春鹼
  • 長春新鹼
  • Vindesine

第5章長春花生物鹼化合物市場：依最終用戶分類

  • 市場概況
  • 醫院
  • 診所
  • 學術研究所

第6章長春花生物鹼化合物市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國長春花生物鹼化合物市場
    • 加拿大長春花生物鹼化合物市場
    • 墨西哥長春花生物鹼化合物市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國長春花生物鹼化合物市場
    • 法國長春花生物鹼化合物市場
    • 英國長春花生物鹼化合物市場
    • 義大利長春花生物鹼化合物市場
    • 西班牙長春花生物鹼化合物市場
    • 其他歐洲長春花生物鹼化合物市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本長春花生物鹼化合物市場
    • 中國長春花生物鹼化合物市場
    • 澳洲長春花生物鹼化合物市場
    • 印度長春花生物鹼化合物市場
    • 韓國長春花生物鹼化合物市場
    • 其他亞太地區長春花生物鹼化合物市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西長春花生物鹼化合物市場
    • 沙烏地阿拉伯長春花生物鹼化合物市場
    • 南非長春花生物鹼化合物市場
    • 其他拉丁美洲/中東/非洲長春花生物鹼化合物市場

第7章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第8章 公司簡介

  • Accord Healthcare Limited
  • Eli Lilly And Company.
  • Fresenius Kabi AG
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Medline Industries, LP.
  • Pfizer Inc.
  • Pierre Fabre SA
  • Talon Pharmaceuticals
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
簡介目錄
Product Code: A324538

Vinca Alkaloid Compounds Market

The vinca alkaloid compounds market was valued at $81.0 million in 2023 and is projected to reach $161.5 million by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

Vinca alkaloid is a naturally occurring secondary metabolite, majorly extracted from the periwinkle plant Catharanthus roseus. The compound is utilized for its anti-mitotic and anti-microtubule properties. During cell division, vinca alkaloid compounds block the polymerization of beta-tubulin, a protein necessary to provide structural support during cell division. This blockage results in cytotoxicity and cell death. This property of the compounds is utilized as a therapeutic approach for the treatment of various cancers, including lymphomas, leukemias, breast cancer, and lung cancer.

Increase in the prevalence of various cancer forms and advancements in the development of therapeutic drugs are the significant drivers of the vinca alkaloid compounds market. Furthermore, constant R&D efforts toward the generation of medications and treatment solutions for the mitigation of cancer boost the demand for vinca alkaloid compounds. The synthesis of this secondary metabolite using endophytes is projected to be a significant trend in the future. Extraction of vinca alkaloid compounds directly from the plant is highly inefficient and intricate. Contrarily, the process of microbial fermentation of endophytes is a notably feasible and competent procedure, which is anticipated to facilitate and boost the production of anti-cancer drugs in upcoming years.

However, the potential side-effects of vinca alkaloid compounds are severe, including neurotoxicity and myelosuppression. This limits the usage of compounds to a certain extent, hence restraining the development of the market. Moreover, the tumor cells develop a resistance to the drugs derived from vinca alkaloid compounds over long durations, lowering their long-term efficacy and hampering the market growth. On the contrary, innovations in drug development have led to the harnessing of anti-cancerous properties of vinca alkaloid compounds by eliminating their limitations, presenting lucrative opportunities for the expansion of the market. For instance, according to a research paper published on the National Library of Medicine, the side-effects of vinca alkaloid compounds are mitigated using combination therapy, in which the compound is combined with some other chemotherapy drug, enhancing the anti-tumor effect of the cocktail drug.

Segment Review

The vinca alkaloid compounds market is segmented into product type, end user, and region. On the basis of product type, the market is divided into vinblastine, vincristine, and vindesine. As per end user, it is classified into hospitals, clinics, and academic & research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the vincristine segment dominated the market in 2023.

As per end user, the hospitals segment accounted for a high market share in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global vinca alkaloid compounds market include Accord Healthcare Limited, Eli Lilly and Company., Fresenius Kabi AG, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Medline Industries, LP., Pfizer Inc., Pierre Fabre S.A, Talon Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Viatris Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Vinblastine
  • Vincristine
  • Vindesine

By End User

  • Hospitals
  • Clinics
  • Academic Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Accord Healthcare Limited
    • Eli Lilly and Company.
    • Fresenius Kabi AG
    • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • Medline Industries, LP.
    • Pfizer Inc.
    • Pierre Fabre S.A
    • Talon Pharmaceuticals
    • Teva Pharmaceutical Industries Limited
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VINCA ALKALOID COMPOUNDS MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Vinblastine
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Vincristine
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Vindesine
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: VINCA ALKALOID COMPOUNDS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinics
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Academic Research Institutes
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: VINCA ALKALOID COMPOUNDS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Vinca Alkaloid Compounds Market
      • 6.2.5.1. Market Size and Forecast, By Product Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Vinca Alkaloid Compounds Market
      • 6.2.6.1. Market Size and Forecast, By Product Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Vinca Alkaloid Compounds Market
      • 6.2.7.1. Market Size and Forecast, By Product Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Vinca Alkaloid Compounds Market
      • 6.3.5.1. Market Size and Forecast, By Product Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Vinca Alkaloid Compounds Market
      • 6.3.6.1. Market Size and Forecast, By Product Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Vinca Alkaloid Compounds Market
      • 6.3.7.1. Market Size and Forecast, By Product Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Vinca Alkaloid Compounds Market
      • 6.3.8.1. Market Size and Forecast, By Product Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Vinca Alkaloid Compounds Market
      • 6.3.9.1. Market Size and Forecast, By Product Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Vinca Alkaloid Compounds Market
      • 6.3.10.1. Market Size and Forecast, By Product Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Vinca Alkaloid Compounds Market
      • 6.4.5.1. Market Size and Forecast, By Product Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Vinca Alkaloid Compounds Market
      • 6.4.6.1. Market Size and Forecast, By Product Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Vinca Alkaloid Compounds Market
      • 6.4.7.1. Market Size and Forecast, By Product Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Vinca Alkaloid Compounds Market
      • 6.4.8.1. Market Size and Forecast, By Product Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Vinca Alkaloid Compounds Market
      • 6.4.9.1. Market Size and Forecast, By Product Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Vinca Alkaloid Compounds Market
      • 6.4.10.1. Market Size and Forecast, By Product Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Vinca Alkaloid Compounds Market
      • 6.5.5.1. Market Size and Forecast, By Product Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Vinca Alkaloid Compounds Market
      • 6.5.6.1. Market Size and Forecast, By Product Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Vinca Alkaloid Compounds Market
      • 6.5.7.1. Market Size and Forecast, By Product Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Vinca Alkaloid Compounds Market
      • 6.5.8.1. Market Size and Forecast, By Product Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Accord Healthcare Limited
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Eli Lilly And Company.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Fresenius Kabi AG
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Medline Industries, LP.
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Pfizer Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Pierre Fabre S.A
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Talon Pharmaceuticals
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Teva Pharmaceutical Industries Limited
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Viatris Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments